OrganaBio Launches Contract Cell Therapy Manufacturing Ops

SourceContract Pharma
Date Published06/20/2022
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name OrganaBio, LLC
Parent companyOrganaBio, LLC
Type of work Manufacturing
Reshoring category:Reshoring
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2022
Domestically, the work will be done:In-house
City reshored to:South Miami
State(s) reshored to:FL
If relevant, work nearshored to:-
Product(s) reshoredcell therapy
What domestic positive factors made reshoring more attractive?Higher productivity, Impact on domestic economy
Find Reshoring Articles